Hypermarcas (OTCMKTS:HYPMY) Sees Large Volume Increase – Time to Buy?

Hypermarcas (OTCMKTS:HYPMY) saw an uptick in trading volume on Monday . Approximately 53,617 shares traded hands during trading, an increase of 170% from the previous session’s volume of 19,840 shares.The stock last traded at $4.56 and had previously closed at $4.5050.

Analyst Upgrades and Downgrades

Separately, Jefferies Financial Group upgraded shares of Hypermarcas to a “strong-buy” rating in a report on Monday, July 20th. One analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy”.

Hypermarcas Stock Performance

The company has a current ratio of 1.86, a quick ratio of 1.26 and a debt-to-equity ratio of 0.50. The stock’s 50-day moving average price is $4.25 and its 200-day moving average price is $4.30. The company has a market capitalization of $3.37 billion, a P/E ratio of 9.56 and a beta of 0.71.

Hypermarcas (OTCMKTS:HYPMY) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.01. Hypermarcas had a return on equity of 12.68% and a net margin of 19.77%. As a group, equities analysts expect that Hypermarcas will post 0.53 EPS for the current year.

About Hypermarcas

Hypermarcas SA was a Brazilian consumer health and pharmaceutical company that developed, manufactured and marketed branded products for healthcare, personal care and consumer markets. Its portfolio historically included over-the-counter medicines, prescription products, vitamins, toiletries, cosmetics and other household or personal-care brands.

The company expanded through acquisitions and operated primarily in Brazil, building a broad portfolio of locally recognized brands. In the mid-2010s, Hypermarcas began divesting its non-pharmaceutical businesses to concentrate on healthcare and medicines.